<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="177173">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788892</url>
  </required_header>
  <id_info>
    <org_study_id>CLTR0308-204</org_study_id>
    <nct_id>NCT00788892</nct_id>
  </id_info>
  <brief_title>Trial of CPX-351 in Newly Diagnosed Elderly AML Patients</brief_title>
  <official_title>Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celator Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celator Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates if CPX-351 will be a) more effective than the standard AML treatment
      and b) more tolerable than the standard AML treatment regimens.

      The study compares the investigational product CPX-351 vs the standard treatment for AML in
      this patients age group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, open-label, parallel-arm, fixed-dose, standard therapy
      controlled Phase IIB trial. Study enrollment duration is expected to be approximately 12-18
      months. On entry, patients are randomized to receive either CPX-351 or standard induction
      treatment with cytarabine and daunorubicin(&quot;7 and 3&quot; regimen).

      Patients are stratified to balance the likelihood of obtaining a CR and the duration of CR
      between the two arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission Rate</measure>
    <time_frame>Following 1st induction, following 2nd induction if applicable</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Duration</measure>
    <time_frame>Following achievement of CR and up to 2 years from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Up to 2 years from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 2 years</measure>
    <time_frame>Up to 2 years from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of stem cell transplant</measure>
    <time_frame>Up to 2 years from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early induction mortality at day 30 and at day 60 from start of 1st induction</measure>
    <time_frame>day 30 and day 60 from 1st induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late mortality</measure>
    <time_frame>following Day 90 from 1st induction</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A: CPX-351</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Cytarabine + Daunorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;7 + 3&quot; regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5 as a 90 minute infusion</description>
    <arm_group_label>Arm A: CPX-351</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine at a dose of 100mg/m2/day for 7 days</description>
    <arm_group_label>Arm B: Cytarabine + Daunorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Daunorubicin at dose of 60mg/m2 for 3 days</description>
    <arm_group_label>Arm B: Cytarabine + Daunorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥60 and &lt;76 years at the time of diagnosis of AML

          -  Pathological confirmation of AML

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Laboratory values fulfilling the following:

        Serum creatinine &lt; 2.0 mg/dL Serum total bilirubin &lt; 2.0 mg/dL Serum alanine
        aminotransferase or aspartate aminotransferase &lt; 150 IU/liter Note: If elevated liver
        enzymes are related to disease; contact medical monitor to discuss.

          -  Cardiac ejection fraction &gt; 50% by echocardiography or MUGA scan

        Exclusion Criteria:

          -  Patients with locally advanced or metastatic solid tumors ≤5 years from initial
             diagnosis are excluded. (Patients with locally advanced or metastatic solid tumors &gt;5
             years from initial diagnosis, for whom the investigator has no clinical suspicion of
             active disease for &gt;2 years before randomization are eligible)

          -  Prior treatment for AML; only hydroxyurea is permitted (see below)

          -  Acute promyelocytic leukemia [t(15;17)] or favorable cytogenetics, including t(8;21)
             or inv16 if known at the time of randomization

          -  Patients with a prior anthracycline exposure of greater than 368 mg/m2 daunorubicin
             (or equivalent)

          -  Any serious medical condition, laboratory abnormality or psychiatric illness that
             would prevent obtaining informed consent

          -  Administration of any antineoplastic therapy within 4 weeks of the first CPX-351
             dose; in the event of rapidly proliferative disease use of hydroxyurea is permitted
             until 24 hours before the start of study treatment

          -  Clinical evidence of active CNS leukemia

          -  Patients with history of and/or current evidence of myocardial impairment (e.g.
             cardiomyopathy, ischemic heart disease, significant valvular dysfunction,
             hypertensive heart disease, and congestive heart failure) resulting in heart failure
             by New York Heart Association Class III or IV staging

          -  Active and uncontrolled infection. Patients with an infection receiving treatment
             with antibiotics may be entered into the study if they are afebrile and
             hemodynamically stable for 72 hrs.

          -  Current evidence of invasive fungal infection (blood or tissue culture); HIV or
             active hepatitis C infection

          -  Hypersensitivity to cytarabine, daunorubicin or liposomal products

          -  History of Wilson's disease or other copper-related disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey E Lancet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Jacksonville Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Group of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H.Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Francis Hospital</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New Jersey Cancer Associates</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weil Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College, Division of Oncology</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center/Mecklenburg Medical Group</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg Cancer Center</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center at the University of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedlert Hospital/Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Research Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elisabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Department of Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 25, 2016</lastchanged_date>
  <firstreceived_date>November 10, 2008</firstreceived_date>
  <firstreceived_results_disposition_date>May 16, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute</keyword>
  <keyword>Myeloid</keyword>
  <keyword>Leukemia</keyword>
  <keyword>elderly</keyword>
  <keyword>Newly</keyword>
  <keyword>Diagnosed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
